An Open-Label, Phase 1/Phase 2 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of the DNA Minor Groove Binding Agent SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia
Latest Information Update: 07 Nov 2021
At a glance
- Drugs SG 2000 (Primary)
- Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors Spirogen
- 20 Nov 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
- 20 Jan 2014 New trial record